KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment (2017 - 2025)

Amneal Pharmaceuticals has reported Asset Writedowns and Impairment over the past 9 years, most recently at $26.6 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $26.6 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $73.1 million (up 7846.2% YoY), and the annual figure for FY2025 was $86.0 million, up 9243.7%.
  • Asset Writedowns and Impairment for Q4 2025 was $26.6 million at Amneal Pharmaceuticals, up from $22.8 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for AMRX hit a ceiling of $45.3 million in Q4 2022 and a floor of -$15.9 million in Q4 2021.
  • Median Asset Writedowns and Impairment over the past 5 years was $14.8 million (2023), compared with a mean of $14.4 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: plummeted 2117.26% in 2021 and later surged 2472.72% in 2025.
  • Amneal Pharmaceuticals' Asset Writedowns and Impairment stood at -$15.9 million in 2021, then soared by 385.18% to $45.3 million in 2022, then plummeted by 77.35% to $10.3 million in 2023, then tumbled by 91.04% to $920000.0 in 2024, then surged by 2795.22% to $26.6 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $26.6 million (Q4 2025), $22.8 million (Q3 2025), and $23.7 million (Q1 2025) per Business Quant data.